The effects of GBP1 in cancer appear to be highly context-dependent, however, as its upregulation is associated with decreased progression in some cancer types, such as breast and colorectal cancer (51–53), but is linked with increased progression, metastasis, and treatment resistance in other cancer types, such as ovarian cancer and glioblastoma (17, 54). Here, GBP1 is linked to cancer.